Publications by authors named "C Cruciani"

Claim this Profile
A
Administration of belimumab prior to standard immunosuppression in patients with early active lupus hinders accrual of new EULAR/ACR criteria within the first 12 months of treatment.
Mariele Gatto, Claudio Cruciani, Elisa Bellis, Pietro Francesco Gavino Pilo, Massimo Radin

Lupus Sci Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal Anti- IgG Responses in Multiple Sclerosis Patients Linked to CSF Immune Cells and Disease Activity.
Carolina Cruciani, Camille Mathé, Marco Puthenparampil, Paula Tomas-Ojer, Maria José Docampo

J Clin Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis.
Mariele Gatto, Giulia Frontini, Claudia Furlan, Marta Calatroni, Claudio Cruciani

Ann Rheum Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.
Anna Gamba, Roberto Depascale, Elisabetta Zanatta, Luana Ienna, Claudio Cruciani

Clin Rheumatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention.
Mariele Gatto, Margherita Zen, Claudio Cruciani, Luca Iaccarino, Andrea Doria

Autoimmun Rev· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis